Factors Associated with the Evolution of Superficial Vein Thrombosis and Its Impact on the Quality of Life: Results from a Prospective, Unicentric Study

• Published in: Journal of vascular diseases 2024-01, Vol.3 (1), p.1-10
• Main Authors: Ros Gómez, Blanca, Gómez-López, Javier, Quintana-Díaz, Manuel, Calvo Sevilla, Sheila Victoria, Rodríguez-Fuertes, Pablo, Tejeda-Jurado, Fabian, Berrocal-Espinosa, Paula, Martínez-Ballester, Juan Francisco, Rodríguez-Roca, Sonia, Rivera Núñez, María Angélica, Martínez Virto, Ana M., Martín-Vega, Alberto, Fernández-Capitán, Carmen, Salgueiro-Origlia, Giorgina, Marín-Baselga, Raquel, Hernández, Alicia Lorenzo, Bueso, Teresa Sancho, Puchades Rincón de Arellano, Ramón, Gutiérrez-Sancerni, Belén, Díez-Vidal, Alejandro, Carrasco-Molina, Sergio, Tung-Chen, Yale
• Format: Article
• Language: English
• Subjects: anticoagulants; outcome; pulmonary embolism; quality of life; superficial vein thrombosis; venous thrombosis
• ISSN: 2813-2475; 2813-2475
• DOI: 10.3390/jvd3010001

Background: Superficial venous thrombosis (SVT) is a common clinical condition caused by inflammation and the presence of a thrombus inside a superficial vein. It has traditionally been considered a benign and banal disorder, although it can progress or can be associated with thromboembolic disease of deep territories in up to 20%, asymptomatic or symptomatic pulmonary embolism (PE), especially if it affects the main trunk of the internal saphenous vein. The impact of deep vein thrombosis on the quality of life and its sequelae have long been described in the literature; however, they have not been studied in superficial vein thrombosis. Objectives: We aimed to evaluate the risk factors, management, and complications of SVT and its impact on the quality of life of our patients. Methods: Observational, prospective, single-center study to evaluate the management of SVT. The ultrasound (US) was performed initially on symptomatic patients, during treatment with low-molecular-weight heparin (LMWH), at a follow-up, and at the end of 45 days of treatment. A quality-of-life questionnaire was administered to determine the risk factors, management, and complications of SVT at the moment of diagnosis and at the end of treatment. We included patients referred from the emergency department to a monographic consultation for thromboembolic disease, over 18 years of age with a diagnosis of acute SVT symptomatic, without contraindication to initiate anticoagulation. Results: In total, 63 patients were evaluated between October 2020 and April 2022. The mean age was 65.8 years (SD 13.5), of which 35 were women (55.6%), 39 presented cardiovascular risk factors (61.9%), 25 had a history of previous personal venous thromboembolism (VTE) (39.7%), and 10 had obesity (15.9%), 47 had chronic venous insufficiency or varicose veins (74.9%). During follow-up with ultrasound, 39.7% had partial revascularization, and at discharge, 63.5% had permeabilized the thrombosis against 19% who had residual thrombosis or progression of thrombosis. There was a positive correlation between mobility parameters and improvement in the performance of daily activities (rho = 0.35; p = 0.012) and with improvement in pain/discomfort (rho = 0.37; p = 0.007). An improvement in pain parameters was statistically significantly related to a global assessment health perception (rho = 0.48; p < 0.001). Anxiety and depression parameters were related to a global assessment health perception (rho = 0.462; p = 0.001)